In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Viridian Therapeutics Inc’s stock clocked out at $24.42, up 8.29% from its previous closing price of $22.55. In other words, the price has increased by $8.29 from its previous closing price. On the day, 2.62 million shares were traded. VRDN stock price reached its highest trading level at $24.828 during the session, while it also had its lowest trading level at $22.33.
Ratios:
To gain a deeper understanding of VRDN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 11.01 and its Current Ratio is at 11.01. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.03.
On December 19, 2024, Wells Fargo Downgraded its rating to Equal Weight which previously was Overweight and also lowered its target price recommendation from $37 to $27.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 23 ’25 when Fairmount Funds Management LLC bought 454,545 shares for $22.00 per share. The transaction valued at 9,999,990 led to the insider holds 3,914,458 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VRDN now has a Market Capitalization of 2328884224 and an Enterprise Value of 1490096384. For the stock, the TTM Price-to-Sale (P/S) ratio is 7577.78 while its Price-to-Book (P/B) ratio in mrq is 6.11. Its current Enterprise Value per Revenue stands at 4885.562 whereas that against EBITDA is -4.015.
Stock Price History:
The Beta on a monthly basis for VRDN is 0.95, which has changed by -0.087414026 over the last 52 weeks, in comparison to a change of 0.13367426 over the same period for the S&P500. Over the past 52 weeks, VRDN has reached a high of $27.20, while it has fallen to a 52-week low of $9.90. The 50-Day Moving Average of the stock is 16.59%, while the 200-Day Moving Average is calculated to be 44.67%.
Shares Statistics:
It appears that VRDN traded 1.03M shares on average per day over the past three months and 1987440 shares per day over the past ten days. A total of 93.09M shares are outstanding, with a floating share count of 83.85M. Insiders hold about 9.93% of the company’s shares, while institutions hold 94.03% stake in the company. Shares short for VRDN as of 1760486400 were 9986922 with a Short Ratio of 9.70, compared to 1757894400 on 11000468. Therefore, it implies a Short% of Shares Outstanding of 9986922 and a Short% of Float of 12.770000000000001.
Earnings Estimates
Currently, 1.0 analysts are dedicated to thoroughly evaluating and rating the performance of Viridian Therapeutics Inc (VRDN) in the stock market.The consensus estimate for the next quarter is -$1.11, with high estimates of -$0.92 and low estimates of -$1.2.
Analysts are recommending an EPS of between -$2.96 and -$4.97 for the fiscal current year, implying an average EPS of -$4.11. EPS for the following year is -$3.9, with 10.0 analysts recommending between -$2.9 and -$4.99.
Revenue Estimates
Based on 13 analysts’ estimates, the company’s revenue will be $52.52M in the next fiscal year. The high estimate is $153M and the low estimate is $300k.
